TABLE 1.
Clinical characteristics
| BCT | Mastectomy | P value | |
|---|---|---|---|
| No. of patients (N) | 448 | 198 | |
| Median follow-up (months) | 79.7 | 77.1 | |
| Age (years) | <0.001 | ||
| ≤50 | 155 (35 %) | 104 (53 %) | |
| >50 | 293 (65 %) | 94 (47 %) | |
| Race | 0.040 | ||
| Non-black | 391 (87 %) | 184 (93 %) | |
| Black | 57 (13 %) | 14 (7 %) | |
| T-stage | 0.023 | ||
| Tmic/T1a/T1b | 124 (28 %) | 65 (33 %) | |
| T1c | 210 (47 %) | 70 (35 %) | |
| T2 | 114 (25 %) | 63 (32 %) | |
| LVI | 0.042 | ||
| No | 389 (87 %) | 156 (79 %) | |
| Yes | 59 (13 %) | 38 (19 %) | |
| Unknowna | 0 (0 %) | 4 (2 %) | |
| Grade | 0.586 | ||
| 1 and 2 | 47 (10 %) | 24 (12 %) | |
| 3 | 401 (90 %) | 174 (88 %) | |
| BRCA | <0.001 | ||
| Not tested | 380 (85%) | 149 (76%) | |
| Tested negative | 48 (11%) | 22 (11%) | |
| Polymorphism | 2 (0.4%) | 0 (0%) | |
| BRCA1 mutation | 13 (3%) | 23 (12%) | |
| BRCA2 mutation | 3 (0.7%) | 6 (3%) | |
| Axillary surgery | <0.001 | ||
| Sentinel lymph node biopsy | 414 (92 %) | 151 (76 %) | |
| Axillary dissection | 34 (8 %) | 47 (24 %) | |
| Chemotherapy | 0.444 | ||
| No | 88 (20 %) | 33 (17 %) | |
| Yes | 360 (80 %) | 165 (83 %) | |
| Chemotherapy regimen | 0.586 | ||
| Anthracycline/taxane-based | 148 (33 %) | 91 (46 %) | |
| Anthracycline-based (no taxane) | 56 (13 %) | 14 (7 %) | |
| CMF | 142 (32 %) | 51 (26 %) | |
| Other | 14 (3 %) | 9 (5 %) | |
| Radiation | <0.001 | ||
| No | 0 (0 %) | 198 (100 %) | |
| Yes | 448 (100 %) | 0 (0 %) |
BCT breast-conserving therapy, LVI lymphovascular invasion, CMF cyclophosphamide methotrexate fluorouracil
a
Unknowns were removed from the test